PRLH

Across TCGA pan-cancer cohorts, PRLH RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of PRLH’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where PRLH RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRLH is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

UCEC, LUAD, and BRCA are the cancer types where PRLH tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRLH RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	+0.779	.001	8	view →
LUAD	Male	All	−0.683	<.001	7	view →
BRCA	All	III,IV	+0.616	<.001	6	view →
LUSC	All	All	−0.349	<.001	5	view →
PAAD	All	All	+0.515	.004	2	view →
STAD	All	All	+0.103	.039	2	view →
KIRC	All	II,III,IV	+0.026	.046	2	view →
HNSC	All	II,III,IV	−0.020	.043	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

PRLH–UCEC

Open the UCEC breakdown →